April 21 (Reuters) - Dublin-based Perrigo Company Plc said its board unanimously rejected a $205 per share offer from generic drugmaker Mylan NV, saying the bid substantially undervalued the company.
Perrigo said Mylan's offer did not take into account Perrigo's 2.48 billion euros ($2.66 billion) acquisition of Omega Pharma and new products that are expected to generate about $1 billion in revenue.
18:05 DP World, Quebec's Caisse to create C$5 billion investment vehicle10
15:14 Russia central bank: hackers stole over 2 billion roubles from accounts in central bank10
06:52 France's Carrefour eyes second-quarter 2017 4.5 billion euros IPO of Carmila arm: report13
23:59 Samsung Electronics says reviewing shift to holding company structure14